These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 25885255)

  • 1. Src family kinases interfere with dimerization of STAT5A through a phosphotyrosine-SH2 domain interaction.
    Fahrenkamp D; de Leur HS; Küster A; Chatain N; Müller-Newen G
    Cell Commun Signal; 2015 Feb; 13():10. PubMed ID: 25885255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells.
    Chatain N; Ziegler P; Fahrenkamp D; Jost E; Moriggl R; Schmitz-Van de Leur H; Müller-Newen G
    Oncogene; 2013 Aug; 32(31):3587-97. PubMed ID: 22926520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
    Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia.
    Liao Z; Gu L; Vergalli J; Mariani SA; De Dominici M; Lokareddy RK; Dagvadorj A; Purushottamachar P; McCue PA; Trabulsi E; Lallas CD; Gupta S; Ellsworth E; Blackmon S; Ertel A; Fortina P; Leiby B; Xia G; Rui H; Hoang DT; Gomella LG; Cingolani G; Njar V; Pattabiraman N; Calabretta B; Nevalainen MT
    Mol Cancer Ther; 2015 Aug; 14(8):1777-93. PubMed ID: 26026053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCR-ABL affects STAT5A and STAT5B differentially.
    Schaller-Schönitz M; Barzan D; Williamson AJ; Griffiths JR; Dallmann I; Battmer K; Ganser A; Whetton AD; Scherr M; Eder M
    PLoS One; 2014; 9(5):e97243. PubMed ID: 24836440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SH2-containing adapter protein GRB10 interacts with BCR-ABL.
    Bai RY; Jahn T; Schrem S; Munzert G; Weidner KM; Wang JY; Duyster J
    Oncogene; 1998 Aug; 17(8):941-8. PubMed ID: 9747873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive interactions between STAP-1 and BCR-ABL influence chronic myeloid leukemia cell proliferation and survival.
    Ishiura M; Kitai Y; Kashiwakura JI; Muromoto R; Toda J; Ichii M; Oritani K; Matsuda T
    Biochem Biophys Res Commun; 2021 Jun; 556():185-191. PubMed ID: 33845308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia.
    Kollmann S; Grundschober E; Maurer B; Warsch W; Grausenburger R; Edlinger L; Huuhtanen J; Lagger S; Hennighausen L; Valent P; Decker T; Strobl B; Mueller M; Mustjoki S; Hoelbl-Kovacic A; Sexl V
    Leukemia; 2019 Jul; 33(7):1583-1597. PubMed ID: 30679796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells.
    Nieborowska-Skorska M; Slupianek A; Skorski T
    Oncogene; 2000 Aug; 19(36):4117-24. PubMed ID: 10962572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of Y177 and Nuclear Translocation of Bcr-Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells.
    Li Q; Huang Z; Gao M; Cao W; Xiao Q; Luo H; Feng W
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
    Roumiantsev S; de Aos IE; Varticovski L; Ilaria RL; Van Etten RA
    Blood; 2001 Jan; 97(1):4-13. PubMed ID: 11133737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes.
    Peng Z; Luo HW; Yuan Y; Shi J; Huang SF; Li CL; Cao WX; Huang ZG; Feng WL
    Oncol Rep; 2011 May; 25(5):1381-8. PubMed ID: 21369701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
    Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
    Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.
    Casetti L; Martin-Lannerée S; Najjar I; Plo I; Augé S; Roy L; Chomel JC; Lauret E; Turhan AG; Dusanter-Fourt I
    Cancer Res; 2013 Apr; 73(7):2052-8. PubMed ID: 23400594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr/Abl kinase activity.
    Jacobberger JW; Sramkoski RM; Frisa PS; Ye PP; Gottlieb MA; Hedley DW; Shankey TV; Smith BL; Paniagua M; Goolsby CL
    Cytometry A; 2003 Aug; 54(2):75-88. PubMed ID: 12879454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STAP-2 interacts with and modulates BCR-ABL-mediated tumorigenesis.
    Sekine Y; Ikeda O; Mizushima A; Ueno Y; Muromoto R; Yoshimura A; Kanakura Y; Oritani K; Matsuda T
    Oncogene; 2012 Oct; 31(40):4384-96. PubMed ID: 22231445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis.
    Nieborowska-Skorska M; Wasik MA; Slupianek A; Salomoni P; Kitamura T; Calabretta B; Skorski T
    J Exp Med; 1999 Apr; 189(8):1229-42. PubMed ID: 10209040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcr-abl regulates Stat5 through Shp2, the interferon consensus sequence binding protein (Icsbp/Irf8), growth arrest specific 2 (Gas2) and calpain.
    Hjort EE; Huang W; Hu L; Eklund EA
    Oncotarget; 2016 Nov; 7(47):77635-77650. PubMed ID: 27769062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.
    Chai SK; Nichols GL; Rothman P
    J Immunol; 1997 Nov; 159(10):4720-8. PubMed ID: 9366395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.